160 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings? http://www.zacks.com/stock/news/405507/whats-in-store-for-ani-pharmaceuticals-anip-q1-earnings?cid=CS-ZC-FT-405507 Apr 30, 2019 - ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.
What's in Store for BioSpecifics (BSTC) This Earnings Season? http://www.zacks.com/stock/news/405553/whats-in-store-for-biospecifics-bstc-this-earnings-season?cid=CS-ZC-FT-405553 Apr 30, 2019 - BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
What's in Store for Bayer (BAYRY) This Earnings Season? http://www.zacks.com/stock/news/390421/whats-in-store-for-bayer-bayry-this-earnings-season?cid=CS-ZC-FT-390421 Apr 22, 2019 - Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal http://www.zacks.com/stock/news/382518/biotech-stock-roundup-gild-collaborates-on-nash-fcsc-surges-on-deal?cid=CS-ZC-FT-382518 Apr 17, 2019 - Key highlights of the past week are collaborations and pipeline updates.
Gilead to Collaborate with Novo Nordisk for NASH Treatment http://www.zacks.com/stock/news/381020/gilead-to-collaborate-with-novo-nordisk-for-nash-treatment?cid=CS-ZC-FT-381020 Apr 15, 2019 - Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data http://www.zacks.com/stock/news/370133/sangamo-rises-on-positive-phase-i-ii-hemophilia-study-data?cid=CS-ZC-FT-370133 Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
What's in the Cards for Aeterna (AEZS) This Earnings Season? http://www.zacks.com/stock/news/357560/whats-in-the-cards-for-aeterna-aezs-this-earnings-season?cid=CS-ZC-FT-357560 Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus http://www.zacks.com/stock/news/357166/ophthotechs-opht-q4-loss-wider-gene-therapy-in-focus?cid=CS-ZC-FT-357166 Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Pages: 1234567...16

<Page 2>